GLPwatch
Victoza for Cardiovascular risk reduction
liraglutide · FDA-approved
Last updated 2026-05-28 15:46 UTCVictoza (liraglutide) is FDA-approved for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
AI summary of the sources below.
| Drug | Victoza (liraglutide) |
|---|---|
| Condition | Cardiovascular risk reduction |
| Approval status | FDA-approved |
| Research papers | 50 |
Victoza is FDA-approved for cardiovascular risk reduction. See the current label on the Victoza page.
Research on liraglutide for cardiovascular risk reduction (50)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- The Discovery and Development of Liraglutide and Semaglutide.
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
- The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
- Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.
- Liraglutide causes large and rapid epicardial fat reduction.
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
- Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
- Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
- A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells.
- Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
- Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
- Liraglutide.
- Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
- Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
- Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.